TNFSF11 and osteoporosis: Beyond osteoporosis, the applicability of RANKL monoclonal antibodies extends to conditions such as fibrous dysplasia, spinal fusion, osteoporotic vertebral compression fractures, and bone metastasis, as indicated in Table 5.